Old Vaccines May Stop the Coronavirus, Study Hints. Scientists Are Skeptical. - The New York Times

---

Old Vaccines May Stop the Coronavirus, Study Hints. Scientists Are Skeptical. - The New York Times Posted: 29 Jul 2020 02:43 PM PDT Billions of dollars are being invested in the development of vaccines against the coronavirus. Until one arrives, many scientists have turned to tried-and-true vaccines to see whether they may confer broad protection, and may reduce the risk of coronavirus infection, as well. Old standbys like the Bacille Calmette-Guerin tuberculosis vaccine and the polio vaccine appear to help train the immune system to respond to a broad variety of infections, including from bacteria, viruses and parasites, experts say. Now a study suggests that people who have received certain routine vaccines in the recent past — including childhood vaccinations like measles-mumps-rubella and polio, as well as adult flu vaccines — have lower coronavirus infection rates than those not recently vaccinated. But many experts greeted the conclusions with skepticism. The paper, an analysis of electronic health records from the Mayo Clinic, was posted online; it has not been through the peer review process and has not been accepted by a medical journal. Critics pointed to numerous methodological problems. It is a retrospective study; as such, it points to an association between vaccinations — a marker of overall good health and healthy behaviors — and lower infection risk. But the study does not prove a cause-and-effect relationship. While scientists generally consider studies like these useful for generating hypotheses that may be worth exploring further, they are far from definitive. The researchers analyzed the immunization records of 137,037 patients who had been tested for infection with the coronavirus, comparing matched pairs of vaccinated and unvaccinated patients who were otherwise similar. Updated 2020-07-30T19:05:08.525Z Patients had lower infection rates if they had recently been given the high-dose flu vaccine or had been vaccinated against polio, measles-mumps-rubella, chickenpox, pneumococcal disease, hepatitis A and hepatitis B, or haemophilus influenzae Type B, compared with those who had not received those vaccines in recent years. The level of risk reduction varied, depending on the vaccine and on how recently the individual had been vaccinated. But generally, the childhood vaccinations were linked to a greater reduction in coronavirus infection than the high-dose flu vaccine given to elderly individuals. And some vaccines, if received five years before the study began, were tied to higher coronavirus infection rates, including the human papillomavirus vaccine and the one against typhoid, as well as the meningococcal vaccine. The researchers went to great pains to account for variables that might have made a difference, including testing rates and geographic variations in coronavirus rates, as well as demographic factors like age, race and ethnicity, though some critics said these efforts fell short. "The hypothesis we are testing is that the immune system memory is stimulated by the vaccine," said one of the authors of the paper, Venky Soundararajan, the founder of nference, a company that uses artificial intelligence to synthesize biomedical information. "Then along comes SARS-CoV-2," he said, "and the immune system is able to get the virus to back off and to clear it, so it can't invade multiple cells and become a full-blown infection." In one dramatic finding, Black patients who had received the pneumococcal disease vaccine five years before the study had a significantly lower risk of testing positive for the coronavirus, compared with similar patients who had not gotten the vaccine. That vaccine protects against 13 types of bacteria, including some that cause pneumonia. The Coronavirus Outbreak › Frequently Asked Questions Updated July 27, 2020 Should I refinance my mortgage? It could be a good idea, because mortgage rates have never been lower. Refinancing requests have pushed mortgage applications to some of the highest levels since 2008, so be prepared to get in line. But defaults are also up, so if you're thinking about buying a home, be aware that some lenders have tightened their standards. What is school going to look like in September? It is unlikely that many schools will return to a normal schedule this fall, requiring the grind of online learning, makeshift child care and stunted workdays to continue. California's two largest public school districts — Los Angeles and San Diego — said on July 13, that instruction will be remote-only in the fall, citing concerns that surging coronavirus infections in their areas pose too dire a risk for students and teachers. Together, the two districts enroll some 825,000 students. They are the largest in the country so far to abandon plans for even a partial physical return to classrooms when they reopen in August. For other districts, the solution won't be an all-or-nothing approach. Many systems, including the nation's largest, New York City, are devising hybrid plans that involve spending some days in classrooms and other days online. There's no national policy on this yet, so check with your municipal school system regularly to see what is happening in your community. Is the coronavirus airborne? The coronavirus can stay aloft for hours in tiny droplets in stagnant air, infecting people as they inhale, mounting scientific evidence suggests. This risk is highest in crowded indoor spaces with poor ventilation, and may help explain super-spreading events reported in meatpacking plants, churches and restaurants. It's unclear how often the virus is spread via these tiny droplets, or aerosols, compared with larger droplets that are expelled when a sick person coughs or sneezes, or transmitted through contact with contaminated surfaces, said Linsey Marr, an aerosol expert at Virginia Tech. Aerosols are released even when a person without symptoms exhales, talks or sings, according to Dr. Marr and more than 200 other experts, who have outlined the evidence in an open letter to the World Health Organization. What are the symptoms of coronavirus? Does asymptomatic transmission of Covid-19 happen? So far, the evidence seems to show it does. A widely cited paper published in April suggests that people are most infectious about two days before the onset of coronavirus symptoms and estimated that 44 percent of new infections were a result of transmission from people who were not yet showing symptoms. Recently, a top expert at the World Health Organization stated that transmission of the coronavirus by people who did not have symptoms was "very rare," but she later walked back that statement. But experts said the findings should be interpreted with great caution. "Retrospective studies are great and they provide some hints, but there are caveats," said Dr. Shyam Kottilil, a professor of medicine with the Institute of Human Virology at the University of Maryland School of Medicine. "It's very difficult to establish causality." Interest in the cross-protective effects of vaccines has led to efforts to repurpose old vaccines that may have potential to provide at least transient protection against the coronavirus until a specific vaccine against SARS-CoV-2 is developed and proven safe and effective, he said. "But nobody knows whether this approach will work unless we test them," Dr. Kottilil said. "To endorse this, you need to do really good randomized clinical trials." There is little incentive for private companies to invest in expensive trials because the old vaccines are cheap and off-patent, he added. [Like the Science Times page on Facebook. | Sign up for the Science Times newsletter.] Dr. Christine Stabell Benn, a professor of global health at the University of Southern Denmark who has studied the potential nonspecific effects of vaccines against infectious diseases, said there is "ample evidence" that live attenuated vaccines can increase resistance to seemingly unrelated infections. But the new paper suffers from many limitations, she added, among them that the authors did not do enough to create comparable groups of vaccinated and unvaccinated individuals, and did not disentangle the effects of various vaccines. She was particularly concerned about the so-called healthy user effect: People who have the means and are anxious about their health are most likely both to get vaccinations and also to be tested for the coronavirus, even without symptoms. That "would lead to strong positive associations between vaccination and having a negative test result," Dr. Benn said in an email. "The authors acknowledge this and do something to mitigate the impact, but it remains a big concern." Carl Zimmer contributed reporting.

Global Polio Vaccine Market 2020 – Impact of COVID-19, Future Growth Analysis and Challenges | Sanofi, GSK, Bibcol, Serum Institute, Tiantan Biological - NJ MMA News Posted: 29 Jul 2020 12:47 PM PDT The global Polio Vaccine market report is an exhaustive research investigation of this business space that has been anticipated to accumulate exceptionally considerable returns before the finish of the conjecture span. The report investigates the Global Polio Vaccine Market and gives knowledge into vital parameters, for example, showcases size, deals volume, income figure. The divisions of the Global Polio Vaccine Market and characteristics insights about these sections notwithstanding the particular drivers energizing the compensation and commercialization scene of this business space have additionally been listed in this report. The continuous COVID-19 outbreak has unfavorably influenced the showcase business with assembling tasks incidentally suspended across significant assembling center points, prompting a considerable log jam in the creation. Significant producers suspended their assembling activities in Asia Pacific region (China, India, South Kore), and European nations. Furthermore, affecting the creation, the continuous pandemic has negatively affected the buyer request. The Major players profiled in this report include: Sanofi GSK Bibcol Serum Institute Tiantan Biological IMBCA Panacea Biotec Ltd Bio-Med Halfkin Bio-Pharmaceuticals Get Free Sample PDF (including full TOC, Tables and Figures) of Polio Vaccine Market @ https://www.apexmarketreports.com/Life-Science/global-polio-vaccine-market-by-product-type-inactivated-407896#sample Global Polio Vaccine Market research report covers important experiences dependent on showcase valuation, advertise size, SWOT Analysis, income conjecture and territorial standpoint of this industry. The examination study gives showcase review, Polio Vaccine market definition, territorial market opportunity, deals and income by area, producing cost investigation, industrial chain, advertise impact factors examination, Polio Vaccine market size gauge, showcase information and graphs and statistics, tables, bar and pie charts, and a lot more for business insight. Market Segmentation, By Type: Inactivated Polio Vaccine (IPV) Oral Polio Vaccine (OPV) Market Segmentation, By Applications: Public Private Market Segmentation, By regions: North America (U.S., Canada, Mexico) South America (Cuba, Brazil, Argentina, and many others.) Europe (Germany, U.K., France, Italy, Russia, Spain, etc.) Asia (China, India, Russia, and many other Asian nations.) Pacific region (Indonesia, Japan, and many other Pacific nations.) Middle East & Africa (Saudi Arabia, South Africa, and many others.) The report incorporates point by point data about market drivers, restrictions, difficulties, threats, and potential development chances of the global Polio Vaccine market. The report comprises of exact subjective data, for example, Porter's five powers, PESTLE Analysis, and worth chain examination. The report comprises of patterns that are foreseen to affect the development of the Polio Vaccine industry market during the forecast period frame somewhere in the range of 2020 and 2027. Assessment of these patterns is remembered for the report, alongside their item advancements. Place Inquiry for Buying or Customization of Report: https://www.apexmarketreports.com/Life-Science/global-polio-vaccine-market-by-product-type-inactivated-407896#inquiry There are 13 Chapters to display the Global Polio Vaccine market: Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overview Chapter 2: Market Competition by Manufacturers Chapter 3: Production by Regions Chapter 4: Consumption by Regions Chapter 5: Production, By Types, Revenue and Market share by Types Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications Chapter 7: Complete profiling and analysis of Manufacturers Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10: Marketing Strategy Analysis, Distributors/Traders Chapter 11: Market Effect Factors Analysis Chapter 12: Market Forecast Chapter 13: Polio Vaccine Research Findings and Conclusion, Appendix, methodology and data source.

You are subscribed to email updates from "types of polio" - Google News. To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States